Sphere Bio Ltd.. (4/9/25). "Press Release: APAC Distribution Network Expanded to Strengthen Presence in Region". Cambridge.

	Region	Asia & Oceania (APAC)
	Organisation	Sphere Bio Ltd.
	Group	Sphere Bio (Group)
	Organisation 2	Cold Spring Biotech Corporation (CN)
	Product	Cyto-Mine® Chroma platform
	Product 2	microfluidics technology
	Index term	1st PhileKorea–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in South Korea by 1st PhileKorea
	Index term 2	As One Corp–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Japan by 1st PhileKorea
	Person	Levitzke, Dale (Sphere Fluidics 202404– CEO before VIzgen + Dropworks + NanoStraing Technologies + Illumina + Helix)
	Person 2	Manikandan, Jay (Sphere Bio 202504 VP Commercial APAC before Bruker Spatial Biology + NanoString)

Operational scale-up accelerates global growth strategy to increase regional access and technical support.

Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company’s global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.

The expansion enhances Sphere Bio’s footprint across key Asian and Pacific markets, improving regional access to its innovative technologies, local support, and technical expertise. The Company has formed partnerships with five new distributors: 1st PhileKorea (South Korea), AS ONE Corporation (Japan), Decode Science (Australia and New Zealand), Everlife Research Instruments (Singapore), and Premas Life Sciences (India and Bangladesh). These new partnerships join an already robust network, including Bang Trading (Thailand), Cold Spring Biotech (Taiwan), and Gene Company (China and Hong Kong).

This strategic scale-up enhances Sphere Bio’s ability to provide localized product support and increase adoption of its growing technology portfolio, including the recently launched Cyto-Mine® Chroma platform and new assay offerings. The investment in new partnerships reflects the Company’s long-term commitment to serving the region and supporting local customers with in-depth expertise.

Dale Levitzke, CEO, Sphere Bio, commented: “2025 is a pivotal year as we scale to meet growing global demand and enter high-growth markets. We have partnered with best-in-class distributors to extend our reach and bring our transformative solutions to more customers worldwide. This expansion supports our mission to accelerate scientific discovery through innovation in single-cell analysis.”

Jay Manikandan, VP Commercial (APAC), Sphere Bio, added: “Our expanded distributor network and enhanced presence reflects our commitment to providing localized customer and technical support across the APAC region. These developments represent an important step in bringing our solutions closer to researchers and advancing global adoption.”

For more information contact:

Dr Claire Cox
Sphere Bio Ltd.
Tel: +44 (0)7365 209 441
Email: [email protected]

About Sphere Bio

Sphere Bio develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.

Sphere Bio’s proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally.

Sphere Bio is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.

For more information contact:
[email protected]
+44 (0) 1223 942053

Record changed: 2025-04-25